EuroBiotech: More Articles of Note


> DBV Technologies revealed it expects to compile the information needed to resubmit a filing for approval of its peanut allergy drug in the third quarter. Shares in DBV rose 13% following the news. Statement 

> Exscientia named Andrew Douglas as its director of data engineering. Release 

> The British Library struck a property development deal that will create life sciences laboratory and office space in London. Statement (PDF)


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Summit Therapeutics dosed the first patient in a phase 3 trial of its treatment for Clostridium difficile infection. Top-line data are due in the second half of 2021. Release (PDF)

> ADC Therapeutics dosed the first patient in a phase 1 trial that is testing its anti-CD19 antibody-drug conjugate in combination with AstraZeneca’s Imfinzi. Statement 

> Markus Dangl joined Achilles Therapeutics as CSO. Dangl worked at Medigene and Roche earlier in his career. Release 

Suggested Articles

Out of options, Tocagen will become Forte Biosciences’ route to the public markets through an all-stock reverse merger.

Reich co-founded Effector and served as its SVP of research but has moved on to take up the CSO position at Turning Point Therapeutics.

BioMarin’s hemophilia A drug has been set an Aug. 21 PDUFA date as the California biotech looks to gain a speedy approval.